This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
English to Spanish - Rates: 0.04 - 0.07 EUR per word English to Catalan - Rates: 0.04 - 0.07 EUR per word Spanish to Catalan - Rates: 0.04 - 0.07 EUR per word Catalan to Spanish - Rates: 0.04 - 0.07 EUR per word
Payment methods accepted
Visa, MasterCard, American Express
Portfolio
Sample translations submitted: 1
English to Spanish: Safety and immunogenicity of a malaria vaccine candidate. Phase I/IIb trial. General field: Medical Detailed field: Medical: Pharmaceuticals
Source text - English BACKGROUND: Malaria remains a leading global health problem that requires the improved use of existing interventions and the accelerated development of new control methods. We aimed to assess the safety, immunogenicity, and initial efficacy of the malaria vaccine XX in infants in Africa.
METHODS: We did a phase I/IIb double-blind randomised trial of 214 infants in Mozambique. Infants were randomly assigned to receive three doses either of XX or the hepatitis B vaccine ZZ at ages 10 weeks, 14 weeks, and 18 weeks of age, as well as routine immunisation vaccines given at 8, 12, and 16 weeks of age. The primary endpoint was safety of the XX during the first 6 months of the study, and analysis was by intention to treat. Secondary endpoints included immunogenicity and analysis of new Plasmodium falciparum infections during a 3-month follow up after the third dose. Time to new infections in the per-protocol cohort were compared between groups using Cox regression models. This study is registered with ClinicalTrials.gov, number xxxx.
FINDINGS: There were 17 children (15.9%; 95% CI 9.5-24.2) with serious adverse events in each group. In the follow-up which ended on March 6, 2007, there were 31 serious adverse events in the XX group and 30 serious adverse events in the ZZ group, none of which were reported as related to vaccination. There were four deaths during this same follow-up period; all of them after the active detection of infection period had finished at study month 6 (two in XX group and two in the ZZ group). XX induced high titres of anti-circumsporozoite antibodies. 68 first or only P falciparum infections were documented: 22 in the XX group and 46 in the control group. The adjusted vaccine efficacy was 65.9% (95% CI 42.6-79.8%, p
Translation - Spanish ANTECEDENTES: La malaria sigue siendo uno de los principales problemas de salud global, que requiere una mejora en el uso de las intervenciones existentes y un desarrollo acelerado de nuevos métodos de control. Nuestro objetivo fue evaluar la seguridad, la inmunogenicidad y la eficacia inicial de la vacuna para la malaria XX en bebés en África.
MÉTODOS: Llevamos a cabo un estudio de fase I/IIb, doble ciego, aleatorizado, con 214 bebés en Mozambique. Los bebés fueron asignados de forma aleatoria para recibir tres dosis de XX o de la vacuna para la hepatitis B ZZ, a la edad de 10, 14 y 18 semanas. Recibieron también las inmunizaciones con vacunas de rutina dadas a las 8, 12 y 16 semanas de vida. La medida principal fue la evaluación de la seguridad de la XX durante los primeros 6 meses del estudio, en un análisis por intención de tratar. Las medidas secundarias incluyeron la inmunogenicidad y el análisis de nuevas infecciones por Plasmodium falciparum durante un período de seguimiento de 3 meses después de la tercera dosis. Los tiempos hasta nuevas infecciones en la cohorte conforme al protocolo (análisis por protocolo) se compararon entre grupos utilizando los modelos de regresión de Cox. El estudio ha sido registrado en ClinicalTrials.gov, número xxxx.
RESULTADOS: En cada grupo hubo 17 bebés (15,9%; IC 95%: 9,5-24,2) que presentaron acontecimientos adversos graves. En el período de seguimiento que finalizó el 6 de marzo de 2007 hubo 31 acontecimientos adversos graves en el grupo XX y 30 en el grupo ZZ, ninguno de los cuales se consideró relacionado a la vacunación. Hubo cuatro muertes durante este mismo período de seguimiento, todas ellas después del mes 6 del estudio, en que el período de detección activa de infección había finalizado (dos en el grupo XX y dos en el grupo ZZ). La XX indujo un elevado título de anticuerpos anti-circumsporozoito. Se documentaron 68 primeras infecciones o infecciones causadas por P. falciparum solo: 22 en el grupo XX y 46 en el grupo control. La eficacia ajustada de la vacuna fue de un 65,9% (IC 95%: 42,6-79,8%, p
More
Less
Experience
Years of experience: 16. Registered at ProZ.com: Sep 2008.
English > Spanish/Catalan translator, specialized on scientific and technical texts.
Doctor with broad range of experience on scientific research, working as a translator of scientific and technical texts, specialized on Medicine, Pharmaceuticals, Biology, Molecular Biology, Biochemistry and Chemistry.PhD in Immunology by the University of Barcelona, area of Molecular Biology and Biochemistry. Great expertise in translating, writing and producing scientific papers for international publications.
My skills on scientific and technical literature, terminology and style, obtained by actually working on the field, allow me to produce high quality translations that guarantee a professional, high quality final product for the costumer.Competitive rates, fast turnaround and confidentiality.
Expertise